Advertisement


Mhairi Copland, PhD, MB BChir, on Blast Phase CML: A Possible Treatment Advance

2019 ASH Annual Meeting & Exposition

Advertisement

Mhairi Copland, PhD, MB BChir, of the University of Glasgow, discusses results of a study on the combination of ponatinib and fludarabine, cytarabine, idarubicin, and G-CSF for patients with blast phase chronic myeloid leukemia, a rare complication with a poor outcome (Abstract 497).



Related Videos

Lymphoma
Immunotherapy

Catherine M. Diefenbach, MD, on Follicular Lymphoma: Polatuzumab Vedotin Plus Obinutuzumab/Lenalidomide

Catherine M. Diefenbach, MD, of the Perlmutter Cancer Center at NYU Langone, discusses a primary analysis of a phase Ib/II trial showing that the novel triplet combination of...

Multiple Myeloma
Immunotherapy

Saad Z. Usmani, MD, on Carfilzomib, Dexamethasone, and Daratumumab for Relapsed or Refractory Myeloma

Saad Z. Usmani, MD, of the Levine Cancer Institute, discusses phase III study findings suggesting that the combination of carfilzomib/dexamethasone/daratumumab represents an ...

Leukemia

Tait D. Shanafelt, MD, on CLL in Younger Patients: Comparing Ibrutinib and Rituximab With FCR

Tait D. Shanafelt, MD, of Stanford University, discusses extended follow-up data that show ibrutinib plus rituximab improved clinical outcomes vs the standard therapy of flud...

Leukemia

Jerald P. Radich, MD, on CML: Predicting Deep Molecular Response to Treatment

Jerald P. Radich, MD, of the Fred Hutchinson Cancer Research Center, discusses a gene-expression model that distinguishes patients with chronic myeloid leukemia who achieved ...

Leukemia
Lymphoma

Jennifer Crombie, MD, on Relapsed or Refractory CLL/SLL: Results From a Phase I Trial of Duvelisib and Venetoclax

Jennifer Crombie, MD, of Dana-Farber Cancer Institute, discusses early study results which showed that duvelisib plus venetoclax showed activity in patients with relapsed or ...

Advertisement

Advertisement



Advertisement